Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 276

1.

Volume increases in putamen associated with positive symptom reduction in previously drug-naive schizophrenia after 6 weeks antipsychotic treatment.

Li M, Chen Z, Deng W, He Z, Wang Q, Jiang L, Ma X, Wang Y, Chua SE, Cheung C, McAlonan GM, Sham PC, Collier DA, Gong Q, Li T.

Psychol Med. 2012 Jul;42(7):1475-83. doi: 10.1017/S0033291711002157. Epub 2011 Oct 26.

PMID:
22030695
2.

Association of cerebral deficits with clinical symptoms in antipsychotic-naive first-episode schizophrenia: an optimized voxel-based morphometry and resting state functional connectivity study.

Lui S, Deng W, Huang X, Jiang L, Ma X, Chen H, Zhang T, Li X, Li D, Zou L, Tang H, Zhou XJ, Mechelli A, Collier DA, Sweeney JA, Li T, Gong Q.

Am J Psychiatry. 2009 Feb;166(2):196-205. doi: 10.1176/appi.ajp.2008.08020183. Epub 2008 Nov 3. Erratum in: Am J Psychiatry. 2009 Feb;166(2):237.

PMID:
18981063
3.

White-matter microstructure in previously drug-naive patients with schizophrenia after 6 weeks of treatment.

Wang Q, Cheung C, Deng W, Li M, Huang C, Ma X, Wang Y, Jiang L, Sham PC, Collier DA, Gong Q, Chua SE, McAlonan GM, Li T.

Psychol Med. 2013 Nov;43(11):2301-9. doi: 10.1017/S0033291713000238. Epub 2013 Feb 27.

PMID:
23442742
4.

Basal ganglia volumes in drug-naive first-episode schizophrenia patients before and after short-term treatment with either a typical or an atypical antipsychotic drug.

Glenthoj A, Glenthoj BY, Mackeprang T, Pagsberg AK, Hemmingsen RP, Jernigan TL, Baaré WF.

Psychiatry Res. 2007 Apr 15;154(3):199-208. Epub 2007 Mar 13.

PMID:
17360162
5.

Dorsal striatal volumes in never-treated patients with first-episode schizophrenia before and during acute treatment.

Emsley R, Asmal L, du Plessis S, Chiliza B, Kidd M, Carr J, Vink M.

Schizophr Res. 2015 Dec;169(1-3):89-94. doi: 10.1016/j.schres.2015.09.014. Epub 2015 Oct 4.

PMID:
26441006
6.

Brain volume changes in first-episode schizophrenia: a 1-year follow-up study.

Cahn W, Hulshoff Pol HE, Lems EB, van Haren NE, Schnack HG, van der Linden JA, Schothorst PF, van Engeland H, Kahn RS.

Arch Gen Psychiatry. 2002 Nov;59(11):1002-10.

PMID:
12418933
7.

Early striatal hypertrophy in first-episode psychosis within 3 weeks of initiating antipsychotic drug treatment.

Chua SE, Deng Y, Chen EY, Law CW, Chiu CP, Cheung C, Wong JC, Lienenkaëmper N, Cheung V, Suckling J, McAlonan GM.

Psychol Med. 2009 May;39(5):793-800. doi: 10.1017/S0033291708004212. Epub 2008 Aug 20.

PMID:
18713487
8.

Regional Abnormality of Grey Matter in Schizophrenia: Effect from the Illness or Treatment?

Yue Y, Kong L, Wang J, Li C, Tan L, Su H, Xu Y.

PLoS One. 2016 Jan 20;11(1):e0147204. doi: 10.1371/journal.pone.0147204. eCollection 2016.

9.

Short-term effects of antipsychotic treatment on cerebral function in drug-naive first-episode schizophrenia revealed by "resting state" functional magnetic resonance imaging.

Lui S, Li T, Deng W, Jiang L, Wu Q, Tang H, Yue Q, Huang X, Chan RC, Collier DA, Meda SA, Pearlson G, Mechelli A, Sweeney JA, Gong Q.

Arch Gen Psychiatry. 2010 Aug;67(8):783-92. doi: 10.1001/archgenpsychiatry.2010.84.

PMID:
20679586
10.
11.

Effects of cannabis and familial loading on subcortical brain volumes in first-episode schizophrenia.

Malchow B, Hasan A, Schneider-Axmann T, Jatzko A, Gruber O, Schmitt A, Falkai P, Wobrock T.

Eur Arch Psychiatry Clin Neurosci. 2013 Nov;263 Suppl 2:S155-68. doi: 10.1007/s00406-013-0451-y. Epub 2013 Oct 2.

PMID:
24085610
12.

Striatal Reward Activity and Antipsychotic-Associated Weight Change in Patients With Schizophrenia Undergoing Initial Treatment.

Nielsen MØ, Rostrup E, Wulff S, Glenthøj B, Ebdrup BH.

JAMA Psychiatry. 2016 Feb;73(2):121-8. doi: 10.1001/jamapsychiatry.2015.2582.

PMID:
26747088
13.

Progressive striatal and hippocampal volume loss in initially antipsychotic-naive, first-episode schizophrenia patients treated with quetiapine: relationship to dose and symptoms.

Ebdrup BH, Skimminge A, Rasmussen H, Aggernaes B, Oranje B, Lublin H, Baaré W, Glenthøj B.

Int J Neuropsychopharmacol. 2011 Feb;14(1):69-82. doi: 10.1017/S1461145710000817. Epub 2010 Aug 12.

PMID:
20701823
14.

Efficacy of iloperidone in the short-term treatment of schizophrenia: a post hoc analysis of pooled patient data from four phase III, placebo- and active-controlled trials.

Citrome L, Meng X, Hochfeld M, Stahl SM.

Hum Psychopharmacol. 2012 Jan;27(1):24-32. doi: 10.1002/hup.1254. Epub 2011 Dec 7.

PMID:
22161738
15.

Structural analysis of the basal ganglia in schizophrenia.

Mamah D, Wang L, Barch D, de Erausquin GA, Gado M, Csernansky JG.

Schizophr Res. 2007 Jan;89(1-3):59-71. Epub 2006 Oct 30.

16.

A follow-up MRI study of the superior temporal subregions in schizotypal disorder and first-episode schizophrenia.

Takahashi T, Suzuki M, Zhou SY, Tanino R, Nakamura K, Kawasaki Y, Seto H, Kurachi M.

Schizophr Res. 2010 Jun;119(1-3):65-74. doi: 10.1016/j.schres.2009.12.006. Epub 2010 Jan 3.

PMID:
20051316
17.

A prospective, open-label study to evaluate symptomatic remission in schizophrenia with risperidone long-acting injectable in Korea.

Lee NY, Kim SH, Cho SJ, Chung YC, Jung IK, Kim CY, Kim DH, Lee DG, Lee YH, Lim WJ, Na YS, Shin SE, Woo JM, Yoon JS, Yoon BH, Ahn YM, Kim YS.

Int Clin Psychopharmacol. 2014 Sep;29(5):279-87. doi: 10.1097/YIC.0000000000000030.

PMID:
24583566
18.

Antipsychotic drug effects on brain morphology in first-episode psychosis.

Lieberman JA, Tollefson GD, Charles C, Zipursky R, Sharma T, Kahn RS, Keefe RS, Green AI, Gur RE, McEvoy J, Perkins D, Hamer RM, Gu H, Tohen M; HGDH Study Group.

Arch Gen Psychiatry. 2005 Apr;62(4):361-70.

PMID:
15809403
19.

Absence of regional brain volume change in schizophrenia associated with short-term atypical antipsychotic treatment.

McClure RK, Carew K, Greeter S, Maushauer E, Steen G, Weinberger DR.

Schizophr Res. 2008 Jan;98(1-3):29-39. Epub 2007 Oct 31.

PMID:
17976957
20.

Brain volume changes after withdrawal of atypical antipsychotics in patients with first-episode schizophrenia.

Boonstra G, van Haren NE, Schnack HG, Cahn W, Burger H, Boersma M, de Kroon B, Grobbee DE, Hulshoff Pol HE, Kahn RS.

J Clin Psychopharmacol. 2011 Apr;31(2):146-53. doi: 10.1097/JCP.0b013e31820e3f58.

PMID:
21346618

Supplemental Content

Support Center